GlassScriptPhysician profile
Lawrence C Swan
NPI 1467402321
$2,440.57
in general payments reported to CMS, 2019-2025
29 companies · $15.96 in 2025
The $15.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $632 · 2021: $568 · 2022: $323 · 2023: $21.64 · 2025: $15.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $875.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $373.28 | 2019-2022 | |
| Pfizer INC. | $156.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.21 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $109.55 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.12 | 2019-2022 | |
| Eisai INC. | $66.30 | 2021 | |
| Lilly USA, LLC | $60.11 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.79 | 2019-2021 | |
| Abbvie INC. | $48.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $44.70 | 2022 | |
| Allergan, INC. | $42.46 | 2020 | |
| Merck Sharp & Dohme LLC | $40.77 | 2019-2020 | |
| Medtronic Minimed, INC. | $40.75 | 2019-2020 | |
| Abbott Laboratories | $37.42 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $34.65 | 2019 | |
| Amarin Pharma, INC. | $31.78 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $24.48 | 2021 | |
| Boston Scientific Corporation | $21.64 | 2023 | Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $21.22 | 2022 | |
| Amgen INC. | $18.36 | 2019 | |
| Daiichi Sankyo INC. | $17.79 | 2022 | |
| Esperion Therapeutics, INC. | $16.93 | 2021 | |
| Glaxosmithkline, LLC. | $16.04 | 2022 | |
| Evoke Pharma, INC. | $13.12 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.93 | 2022 | |
| Clarus Therapeutics INC. | $12.02 | 2021 | |
| Sanofi Pasteur INC. | $11.47 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Swan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.